VCYT Q3 2020 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+0.5% YoY

Gross Profit

$21M66.7% margin

Operating Income

-$4M-13.1% margin

Net Income

-$4M-13.3% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+50.3%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$454M

Total Liabilities

$31M

Stockholders' Equity

$423M

Cash & Equivalents

$345M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$31M	+0.5%
Gross Profit	$21M	$22M	-5.1%
Operating Income	-$4M	-$2M	-130.6%
Net Income	-$4M	-$730,000	-464.9%

Revenue Segments

Product

$2M71%

Biopharmaceutical

$824,00029%